
ITF in Year Two: Where We Are Headed

By Matt Trudeau
President of ITF Therapeutics
2/26/25
ITF’s first year of operations was unforgettable. We worked at breakneck speed to design and implement all the structures, processes, systems, and procedures necessary to bring a therapy to market. It has been gratifying to introduce a treatment option to a rare disease community that has been yearning, for far too long, for meaningful interventions.... Read More

2024 Wrap Up

By ITF Leadership Team
1/8/25
As we kick off 2025, we wanted to take a moment to reflect on the past year. We all feel a deep sense of gratitude to the Duchenne muscular dystrophy (DMD) community.... Read More

On Building a Mission-Focused Company

By Melinda Keegan
Head of US Human Resources
12/13/24
Launching a new medication in the U.S. is no small feat. It requires a diverse team of specialists such as manufacturing experts, regulatory professionals, field representatives who work with physicians and payers, patient advocates who build bridges to the community, and medical teams... Read More

Fraught with Treatment Decisions: How Can We Help?

By Dan O'Connell
VP, Head of US Marketing
11/15/24
I can only imagine what it must feel like to be responsible for treatment decisions on behalf of someone who lives with Duchenne muscular dystrophy (DMD). Whether that person is yourself or someone you love, the stakes are unspeakably high... Read More

A Guest in Your Home

By Matt Trudeau
President of ITF Therapeutics
10/31/24
We've all had interactions at one point or another with the kind of house guests who aren't welcome – those who impose themselves on the scene with little regard for their hosts, primarily focused on what they can gain from the situation. I firmly believe that that kind of behavior is also bad in business... Read More

FDA Approval Granted, Access Denied – Now What?

By Stephanie Trafton
Head of US Value & Access
10/3/24
The United States of America is famous for medical innovation. Our country leads the world in the number of new drugs and medical devices that are given the green light by our government. Unfortunately, this does not mean that every approved new... Read More

What Makes an Expert?

By Scott Baver
Vice President, Head of US Medical Affairs
9/22/24
I have been studying neuroscience and working in the field of neuromuscular disease for more than 20 years. I may have the academic degrees and the work experience to qualify as an "expert," but there's no doubt in my mind that the real experts are you... Read More

A Good Day

By Caroline Allen
Head, US Patient Advocacy & Communications
7/24/24
In the long path to new treatments for Duchenne, today is a good day. A medicine that is designed to interfere with Duchenne’s relentless progression is now officially available in the United States. While I am feeling positive and hopeful because of this... Read More